SGA性低身長症における成長ホルモンの体格および脂質代謝に及ぼす影響 by MATSUOKA Hisafumi et al.
Auxological and Biochemical Continuum of Short
Children Born Small for Gestational Age(SGA)













Auxological and Biochemical Continuum of Short Children Born Small for
Gestational Age (SGA) during Growth Hormone (GH) Treatment
Hisafumi MATSUOKA, Yuki YASUDA and Shigetaka SUGIHARA
Department of Pediatrics, Tokyo Women’s Medical University Medical Center East
(Accepted December 1, 2016)
Introduction: The role of growth hormone (GH) on body composition in Japanese children born small for ges-
tational age (SGA) has not been fully elucidated.
Methods: Every six months, the total GH dose was adjusted: SGA, 33-66 μg/kg/day, or GHD, 25-30 μg/kg/
day. Changes in metabolic parameters (HbA1c, leptin, total cholesterol, low-density lipoprotein cholesterol and
high-density lipoprotein cholesterol) were recorded. Changes in the body mass index standard deviation score
(BMI SDS), BMI percentile, and percent overweight were also evaluated.
Results: Over a 3-year period of GH treatment, significant increases in Δ height SDS and Δ insulin-like
growth factor-I ( IGF-I ) were observed. The HbA1c and leptin levels were generally unaffected. Favorable
changes in the lipid profiles were recorded, and these changes were maintained for the study duration. No ad-
verse changes in BMI SDS, BMI percentile, or percent overweight were noted.
Conclusion: GH treatment had a positive impact on height, and any changes observed in safety parameters,
such as lipid profiles, HbA1c and BMI SD, were considered to be related to the natural course of growth in chil-
dren and to be clinically insignificant.
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Introduction
Small for gestational age (SGA) at birth is a rela-
tively common condition, with approximately 5 % of
all newborns being below －2 standard deviation
scores (SDS) for weight and/or length. While the
majority of these children will demonstrate sponta-
neous catch-up growth in early life, approximately
10 % of children born with SGA will fail to do this
by 3 years of age, and this height deficit is likely to
continue into adulthood, with a final adult height re-
maining below －2 SDS of the mean height１）. Al-
though the mechanism responsible for the stunted
postnatal growth in short children born with SGA is
poorly understood, studies have shown that con-
tinuous or discontinuous treatment with recombi-
nant human growth hormone (GH) at varying dos-
ages accelerates growth significantly in short chil-
dren born with SGA, resulting in catch-up growth
to values within the normal range followed by
growth within their target height percentile２）３）.
Restricted fetal growth, which is often studied us-
ing SGA at birth as a proxy, has been robustly asso-
ciated with high blood pressure, type 2 diabetes,
and coronary artery disease in later life. Several re-
cent epidemiologic studies have reported that SGA
at birth is also associated with greater adiposity
(percentage body fat and fat mass), and obesity, par-
ticularly truncal obesity, during later childhood and
adulthood, suggesting that increased adiposity may
be a step on the causal pathway between restricted
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fetal growth and long-term adult chronic disease
outcomes４）. The mechanisms underlying these risks
are unknown, although it has been postulated that
increased insulin resistance and/or intra-abdominal
fat could be responsible５）. Indeed, insulin resistance
and subsequent hyperinsulinemia are common fea-
tures in children born with SGA who experience a
rapid weight gain.
The aim of this study is to examine body compo-
sition and growth at the start and during 3 years of
GH treatment of short children with SGA and GHD.
We hypothesized that the effect of GH on height
gain, adiposity and lipid profiles would be similar in
both groups.
Patients and Methods
The study population was composed of 16 short
children born with SGA and 30 short children with
growth hormone deficiency (GHD) aged 3-8 years.
The short children born SGA were included after
meeting the following criteria: 1) birth weight and
birth length ＜10th percentile for gestational age; 2)
birth weight SDS or birth length SDS ＜－2 SDS for
gestational age; 3) chronological age ≧3 years; 4)
height SDS for chronological age ＜－2.5 SDS; 5 )
peak GH level of ＞6 ng/mL on at least one GH
provocation test conducted within 1 year, and 6 )
prepubertal children (Tanner stage 1 for both boys
and girls) . GH-deficiency (GHD) was defined as a
peak GH secretion ≦6 ng/mL during two GH
provocation tests. None of the patients had diabetes
insipidus, chromosomal abnormalities, Silver-Russell
syndrome, or dysmorphic syndromes, as estab-
lished by a careful clinical evaluation. All the sub-
jects had normal thyroid function (normal TSH and
FT4 circulating levels ) . Children who had previ-
ously received systemic thyroid hormone or ana-
bolic steroid, adrenocortical steroid and analogue of
gonadotropin-releasing hormone were not eligible
in both groups.
Biosynthetic GH was given subcutaneously once
daily at bedtime using a pen injection system.
Every six months, the total GH dose was adjusted:
SGA, 33-66 μg/kg/day or GHD, 25-30 μg/kg/day.
All the children were seen at our hospital for a
physical examination, including measurements of
standing height and weight at baseline and every 3
months thereafter, by trained observers. Height
was expressed as SDS. Body mass index (BMI :
weight [in kilograms]/height squared [in meters])
was expressed as the SD-score and percentile for
sex and chronological age. Percent overweight was
calculated as follows : ( actual weight ) － ( ideal
weight)/(ideal weight)６）７）. The pubertal stages were
assessed by the same two investigators according
to the Tanner stage using an orchidometer in boys.
Changes in height, IGF-I, BMI SDS, BMI percentile,
and percent overweight were reported at 1, 3, and 6
months and at 1, 2, and 3 years. This report also
presents data on the effect of long-term GH therapy
on the following metabolic parameters : glucose,
HbA1c (glycosylated hemoglobin A1c, NGSP), total
cholesterol (TC), low-density lipoprotein cholesterol
(LDL-C), high-density lipoprotein cholesterol (HDL-
C) and leptin in Japanese children born with SGA
and GHD.
All the analyses were performed using the full
analysis set consisting of all the randomized pa-
tients. The summary statistics (mean with SD) were
calculated for treatment differences (SGA vs GHD,
baseline vs 3 years) in Ht-SDS, IGF-1, leptin, BMI-
SDS, BMI percentile, percent overweight, lipid pa-
rameters and HbA1c for patients who had baseline
and 3-year data (last observation carried forward).
Data were analyzed using 2-sided, 2-sample t-tests
performed at a significance level of p＜0.05.
This study was approved by the institutional eth-




Table 1 lists the baseline clinical data of the 45
children. Both the SGA and the GHD groups had
similar initial characteristics. No significant differ-
ences in baseline data between the SGA and the
GHD groups were found. After three years of GH
treatment, all the children were still getting height
gain and receiving GH treatment.
Height, IGF-I, and leptin
During 3 years of GH treatment, catch-up growth





N, gender (male/female) 14 (7/7) 31 (18/13)
CA, years 7.61 (3.23) 8.62 (3.62)
Height SDS －2.92 (0.41) －2.66 (0.46)
IGF-I, ng/mL 121.5 (50.1) 118.6 (52.2)
Leptin, ng/mL 2.7 (1.5) 3.3 (2.3)
HbA1c, % 4.9 (0.3) 4.9 (0.3)
TC, mg/dl 180 (33) 172 (41)
LDL-C, mg/dl 108 (33) 100 (39)
HDL-C, mg/dl 69 (17) 63 (17)
TSH, μIU/ml 2.27 (1.01) 2.58 (0.96)
f T4, ng/dl 1.39 (0.18) 1.32 (0.16)
BMI SDS －0.87 (1.08) －0.31 (1.13)
BMI percentile 28.8 (26.0) 42.8 (31.6)
percent overweight 0.3 (9.2) 7.4 (15.4)
Results are expressed as means with standard deviations 
in parentheses.
Fig.　1　Time sequence of changes in height (Ht) SDS, IGF-I, and leptin before the start 
of GH treatment and for the first 3 years of treatment in the SGA (circle symbol) and 
GHD (triangle symbol) groups. Note the significant increase in Ht SDS and IGF-I during 
the first year of treatment, with ongoing (although more gradual) increases thereafter in 




－2.92 to －1.60, p＜0.01; GHD: －2.66 to －1.93, p＜
0.01; SGA vs GHD at 3 years, p=0.21) and IGF-I level
(SGA: 121.5 to 359.9, p＜0.01; GHD: 118.6 to 280.8, p＜
0.01; SGA vs GHD at 3 years, p=0.12). No significant
differences in the changes in height SDS or IGF-I
measurements after three years of GH treatment
were seen between the two groups. During the first
6 months, the leptin levels decreased by 25 % in
SGA children, indicating a body fat reduction.
Thereafter, these levels increased to a value that
was not significantly different from the pretreat-
ment values (Fig. 1).
BMI SD, BMI percentile, and percent over-
weight
At the start of GH treatment, the mean SD for
BMI was －0.87, which was lower than zero, indicat-
ing that untreated children born with SGA had a
lean and fragile body mass and reflecting a subopti-
mal nutritional status. After 3 years of GH treat-
ment, it had increased, but not significantly, com-
pared to the baseline value, with values that were
closer to zero. The increment in the BMI SD-score
was not significantly different between these two
groups during GH treatment. The changes in BMI
percentile and percent overweight were not signifi-
cantly different between the GHD group and the
SGA group during the 3-year study period (Fig. 2).
Lipids & HbA1c
The mean pretreatment lipid profiles and HbA1c
levels were normal in both groups. Four children
had a TC level of more than 200 mg/dL, one child
had an LDL cholesterol level of more than 140 mg/
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Fig.　2　Body mass index (BMI) SD-score, BMI percentile and percent overweight using 
reference values for healthy Japanese children according to sex, chronological age, height 
and weight at baseline and during 3 years of GH treatment in the SGA (circle symbol) 
and GHD (triangle symbol) groups.
Fig.　3　Time sequence for changes in total cholesterol, LDL cholesterol, HDL cholesterol 
and HbA1c at baseline and during 3 years of GH treatment in the SGA (circle symbol) 
and GHD (triangle symbol) groups.
dL, and none of the children had an HDL cholesterol
level of less than 40 mg/dL in the SGA group. De-
spite the observed decreases during the 3-year GH
treatment period in the SGA group, the mean TC,
LDL, and HDL measurements did not exceed the
normal limits for healthy children, and the subjects
in this study were considered normotensive. After
3 years of GH treatment for SGA, one of the chil-
dren had an abnormal TC, whereas none of the chil-
dren had an LDL cholesterol level of more than 140
mg/dL and one child had an HDL cholesterol level
of less than 40 mg/dL. The mean HbA1c values had
marginally increased in both groups after 3 years of
GH treatment (0.08 % and 0.17 % in the SGA and
77
―E77―
GHD groups, respectively ) , although none of the
subjects exceeded the upper limit of the HbA1c ref-
erence range (4.3 %-5.8 %) (Fig. 3).
Discussion
We decided to compare SGA children with al-
ready well-described GHD children. It would have
been useful to have two measurements at different
times after the start of GH treatment so as to quan-
tify the effect of GH more precisely in each group８）.
A lack of treatment might provide a psychological
advantage (no injection stress) or a disadvantage
(thoughts that “no one is doing anything about my
short stature”), while the use of placebo injections is
not acceptable to many parents whose SGA chil-
dren have often had varying degrees of traumatic
hospital experiences in the past. Both the SGA and
the GHD children showed similar increases in
height SDS after three years of GH treatment. An
indicator of GH sensitivity, the IGF-I level, was
measured throughout this study; these levels were
low at the start of treatment but increased in a simi-
lar manner in both groups. GH is a crucial regulator
of substrate metabolism during fasting, and its ana-
bolic actions are tightly coupled with energy bal-
ance. A low adiposity in SGA children may reflect a
suboptimal energy balance and may alter their sen-
sitivity to GH.
BMI expressed as the SDS for age, which is a bet-
ter parameter for assessing the degree of over-
weightness since it takes into account age as well as
height, has not been studied extensively in SGA
children. Correction for age is important because
the BMI changes substantially with age, decreasing
during preschool years and then increasing into
adulthood９）１０）. Unfortunately, no reference values
are available for the BMI SD score in untreated
short children born with SGA. Therefore, the natu-
ral development of the BMI SD score in these chil-
dren remains unknown ; consequently, we cannot
prove whether the changes in the BMI SD score
during treatment are caused by GH. In the present
study, however, during the 3 years of treatment,
the height SD score and the IGF-I improved signifi-
cantly, while the BMI SD score, BMI percentile, and
percent overweight did not change. Therefore, it is
likely that the changes in the BMI SD score during
the GH treatment are more a result of the natural
childhood growth of subjects with a short stature
who were born with SGA or that the changes in the
BMI SD score reflect catch-up growth in these chil-
dren, rather than a direct effect of the GH treat-
ment. GH causes the body to utilize fat mass stores
for energy to aid in the production of muscle, which
is proportionally increased in patients receiving GH.
It is possible that GH may have affected body com-
position, as GH promotes the development of mus-
cle over fat, but specific tests such as dual-energy
X-ray absorptiometry would be needed to show
such a change１１）.
Leptin, the first adipocyte hormone identified, in-
fluences food intake through a direct effect on the
hypothalamus. In humans and rodents, plasma
leptin concentrations are strongly correlated with
the BMI１２）. Far from hormonally inert, adipose tis-
sue has, in recent years, been recognized as a major
endocrine organ, as it produces hormones such as
leptin, PAI-1, resistin, and the cytokine TNFα.
Moreover, adipose tissue can affect other organ sys-
tems of the body and may lead to disease. Our
leptin data in SGA is comparable with the results of
fat and muscle measurements made using magnetic
resonance imaging and described by Leger et al.１３）.
They reported an increase in the cross-sectional
area of muscle tissue in 14 prepubertal short chil-
dren born with SGA but without GH deficiency dur-
ing 3 years of GH treatment with 0.2 IU/kg per day
(6 IU/m2 per day). In addition, the adipose tissue
cross-sectional area showed an initial decrease dur-
ing the first year of treatment, followed by an in-
crease during the second and third years to values
similar to those in a control group of GHD children.
GH increases basal lipolysis and increases the activ-
ity of hormone-sensitive lipase, resulting in a rapid
decrease in the adipose area and an increase in
muscle tissue. It seems likely that the reduction in
leptin levels is attributable to the reduction in adi-
pose tissue mass that occurs during GH treatment.
GH deficiency is associated with dyslipidemia.
Barker et al demonstrated a negative correlation
between birth weight and syndrome X (hyperten-
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sion, diabetes mellitus type 2, and hyperlipidemia)
in adult men１４）. Being born with SGA has been asso-
ciated with the onset of hyperlipidemia at a rela-
tively young age later in life１５）hence, we were inter-
ested in the effect of GH therapy on the lipid pro-
files in these patients. The pretreatment levels of
TC and LDL-C in the SGA group were normal, com-
pared with those in the GHD group which were
slightly low. An analysis of the change from the
baseline TC and LDL-C values in a model that in-
cluded the baseline values as covariates showed
treatment differences for TC and LDL, and a clear
trend towards a reduction in both lipid parameters
was evident in the SGA group. In a previous study,
no change in the HDL-C levels was seen during GH
treatment１６）. Further investigations are warranted
to evaluate the impact of GH treatment on lipid pa-
rameters in children born with SGA in greater de-
tail. Long-term monitoring is needed to assess
whether the effects of GH on the lipid profiles of
children with SGA or GHD has long-term benefits
(or risks) for their metabolic health.
GH therapy is known to affect glucose homeosta-
sis and insulin action. Despite slight increases in
HbA1c during the initial 3 years of this study, no
clinically relevant HbA1c changes were observed,
and none of the patients were classified as “diabetic
type ” . SGA children with spontaneous catch-up
growth are at an increased risk of developing type
2 diabetes１７）, in addition to other chronic conditions
that are risk factors for cardiovascular disease.
Therefore, it is encouraging that these data suggest
that in Japanese children born with SGA, prolonged
GH treatment is not associated with the develop-
ment of diabetes. These data are in accordance
with recent studies demonstrating that long-term
GH treatment did not increase the risk of type 2 dia-
betes and metabolic syndrome in young adults born
with SGA１８）. Nevertheless, our data is limited to the
first 3 years of GH therapy, and further studies with
an extended follow-up period lasting until the final
stature has been reached are needed to confirm
that the “non-diabetic type” persists after 3 years of
GH treatment and that the treatment affects the fi-
nal height of children with SGA or GHD.
Conclusion
GH treatment had a positive impact on height,
and any changes observed in safety parameters,
such as lipid profiles, HbA1c and BMI SD, were con-
sidered to be correlated with the natural course of
childhood growth and to be clinically insignificant.
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SGA性低身長症における成長ホルモンの体格および脂質代謝に及ぼす影響
東京女子医科大学東医療センター小児科
マツオカ ヒサフミ ヤ ス ダ ユ ウ キ スギハラ シゲタカ
松岡 尚史・安田 祐希・杉原 茂孝
〔緒言〕SGA 性低身長症小児の体組成に及ぼす成長ホルモン（GH）の影響については，本邦での報告がない．
成長ホルモン分泌不全性低身長（GHD）小児との GH 治療期間中の体格の経時的な比較をすることで検討した．
〔対象と方法〕SGA 群 16 名，GHD 群 30 名を対象として，GH 治療期間中に 6 月ごとに外来受診時に身体計測と
成長関連および糖脂質代謝パラメーターの血液検査を施行して，治療開始前後および両群間で比較検討した．
〔結果〕3 年間にわたる GH 治療期間中，SGA 群では GHD 群と同様に身長 SD スコアおよび IGF-1 は両群ともに
治療開始後，有意に増加したが，糖脂質代謝および血中レプチン値に変化はなかった．BMI SD スコア，BMI パー
センタイル，肥満度の各体格指数は治療前後および両群間で有意な変化を認めなかった．
〔結論〕SGA 性低身長症における GH 治療は有意な身長増加をもたらすが，体格に及ぼす影響はなく自然な成長
パターンでの身長増加効果がある．この間，糖尿病や脂質異常などの副作用出現はみられなかった．
